GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|25|1|19-27

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.25, Iss.1, 2018-01, pp. : 19-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 2, 2014-06 ,pp. : 115-123

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1042-1050

John Wiley & Sons Inc

Access to resources Recommend Favorite

JTK-853, a Novel Non-Nucleoside Hepatitis C Virus Polymerase Inhibitor, Demonstrates a High Genetic Barrier to Resistance in vitro

By  

Intervirology, Vol. 56, Iss. 5, 2013-07 ,pp. : 302-309

Karger

Access to resources Recommend Favorite

Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 59-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 665-673

John Wiley & Sons Inc

Access to resources Recommend Favorite